Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

ABSTRACT: Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

PROVIDER: PRJNA610595 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11245400_1.fastq.gz	Fastqsanger.gz
	SRR11245400_2.fastq.gz	Fastqsanger.gz
	SRR11245401_1.fastq.gz	Fastqsanger.gz
	SRR11245401_2.fastq.gz	Fastqsanger.gz
	SRR11245402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 154

Similar Datasets

Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

Project description:The lack of knowledge about the relationship between tumor genotypes and therapeutic responses remains one of the most important gaps in enabling the effective use of cancer therapies. Here, we couple a multiplexed and quantitative platform with robust statistical methods to enable pharmacogenomic mapping of lung cancer treatment responses in vivo. We uncover a surprisingly complex map of genotype-specific therapeutic responses, with over 20% of possible interactions showing significant resistance or sensitivity. We validate one of these interactions - the resistance of Keap1 mutant tumors to platinum therapy - using a large patient response dataset. Our results highlight the importance of understanding the genetic determinants of treatment responses in the development of precision therapies and define a strategy to identify such determinants.

2021-03-05 | GSE146448 | GEO

Quantitative <i>In Vivo</i> Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.

Project description:The lack of knowledge about the relationship between tumor genotypes and therapeutic responses remains one of the most critical gaps in enabling the effective use of cancer therapies. Here, we couple a multiplexed and quantitative experimental platform with robust statistical methods to enable pharmacogenomic mapping of lung cancer treatment responses in vivo. The complex map of genotype-specific treatment responses uncovered that over 20% of possible interactions show significant resistance or sensitivity. Known and novel interactions were identified, and one of these interactions, the resistance of KEAP1-mutant lung tumors to platinum therapy, was validated using a large patient response data set. These results highlight the broad impact of tumor suppressor genotype on treatment responses and define a strategy to identify the determinants of precision therapies. SIGNIFICANCE: An experimental and analytical framework to generate in vivo pharmacogenomic maps that relate tumor genotypes to therapeutic responses reveals a surprisingly complex map of genotype-specific resistance and sensitivity.

| S-EPMC8416777 | biostudies-literature

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Search for SNPs associated with the pharmacogenomic profile of Benzidazole adverse reactions in Chagas Disease Homo sapiens patients.

2021-03-31 | GSE154421 | GEO

Quantitative in vivo analyses reveal calcium-dependent phosphorylation sites and identifies a novel component of the Toxoplasma invasion motor complex.

Project description:Apicomplexan parasites depend on the invasion of host cells for survival and proliferation. Calcium-dependent signaling pathways appear to be essential for micronemal release and gliding motility, yet the target of activated kinases remains largely unknown. We have characterized calcium-dependent phosphorylation events during Toxoplasma host cell invasion. Stimulation of live tachyzoites with Ca²?-mobilizing drugs leads to phosphorylation of numerous parasite proteins, as shown by differential 2-DE display of ³²[P]-labeled protein extracts. Multi-dimensional Protein Identification Technology (MudPIT) identified ?546 phosphorylation sites on over 300 Toxoplasma proteins, including 10 sites on the actomyosin invasion motor. Using a Stable Isotope of Amino Acids in Culture (SILAC)-based quantitative LC-MS/MS analyses we monitored changes in the abundance and phosphorylation of the invasion motor complex and defined Ca²?-dependent phosphorylation patterns on three of its components--GAP45, MLC1 and MyoA. Furthermore, calcium-dependent phosphorylation of six residues across GAP45, MLC1 and MyoA is correlated with invasion motor activity. By analyzing proteins that appear to associate more strongly with the invasion motor upon calcium stimulation we have also identified a novel 15-kDa Calmodulin-like protein that likely represents the MyoA Essential Light Chain of the Toxoplasma invasion motor. This suggests that invasion motor activity could be regulated not only by phosphorylation but also by the direct binding of calcium ions to this new component.

| S-EPMC3182922 | biostudies-literature

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

Project description:Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

| PRJNA215007 | ENA

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumor

Project description:Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumor

| PRJNA1090069 | ENA

Pharmacogenomic characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers

Project description:MI-773 is a recently developed small-molecule inhibitor of the Mouse Double Minute 2 (MDM2) proto-oncogene. Here we report an integrative pharmacogenomic study to gain further insights into the therapeutic potential of the compound.

2021-10-27 | GSE152529 | GEO

LC/MS-based FFPE tissue-proteomic analyses of early lung adenocarcinoma

Project description:Clinical FFPE tissue proteomic analyses were performed for early lung adenocarcinomas including adenocarcinoma in-situ (AIS), minimally invasive adenocarcinoma (MIA) and lepidic predominant invasive adenocarcinoma (LPA).

2020-01-30 | PXD017334 | JPOST Repository

Pharmacogenomic eQTL mediated by androgen receptor modulators

Project description:Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor  (ER). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ER-positive tumors. However, AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. We performed a genome-wide study to identify genetic context-dependent AR signaling induced by either AR agonist (dihydrotestosterone [DHT]), or AR antagonist (enzalutamide [Enz]), known as pharmacogenomic expression quantitative expression loci (PGx-eQTLs), utilizing a previously well characterized lymphoblastic cell line panel.

2024-01-01 | GSE245417 | GEO

Pharmacogenomic interactions in Glioblastoma cell line models

Project description:Pharmacogenomic interactions in Glioblastoma cell line models

| PRJNA526264 | ENA